Veracyte, Inc.

We received Medicare coverage for our #TrueMRD Monitoring Test for patients with muscle-invasive bladder cancer (MIBC). Available for clinicians to order on June 1, 2026, this marks the commercial launch of Veracyte's first molecular residual disease (#MRD) offering and the only commercially available truly whole-genome MRD test to come to market. 🔗 Read the full press release - investor.veracyte.com/news-releases/… 🔗 Learn about the TrueMRD Monitoring Test for MIBC -  veracyte.com/tests/truemrd-… #MuscleInvasiveBladderCancer #BladderCancer #WholeGenomeSequencing $VCYT Disclaimer - veracyte.com/legal/cautiona…

More than 15 studies on our Decipher portfolio will be presented at #AUA2026, May 15–18 in Washington, DC. Data showcases the growing impact of #DecipherBladder and #DecipherProstate tests in supporting personalized patient care. Press release: investor.veracyte.com/news-releases/… Event info: veracyte.com/company/event/… #UrologicCancer #ProstateCancer #BladderCancer #PrecisionMedicine Disclaimer: veracyte.com/legal/cautiona…

We will report financial results for the first quarter of 2026 on May 5, 2026 at 4:30 PM ET. Join our conference call and webcast to learn more about the financial results and receive a general business update. Access the live audio webcast here: investor.veracyte.com/events-present… #Q1Earnings #FinancialResults #InvestorRelations #Biotech #Diagnostics $VCYT #CancerDiagnostics #PrecisionMedicine Note: this information contains forward-looking statements - veracyte.com/cautionary-not…

Exciting news: the #AfirmaGRID data resource is expanding from 36 to 50 data points to further accelerate scientific discoveries in thyroid nodules and thyroid cancer. The Afirma GRID proprietary research-use-only database is designed to help clinicians advance the understanding of thyroid nodules and thyroid cancer at the molecular level. Afirma GRID data has contributed to a growing number of abstracts presented in collaboration with notable institutions from around the world, with a significant increase in research outputs throughout 2025. 🔬 Afirma GRID data is available through three access pathways. Interested in conducting research or learning more? Learn more -  veracyte.com/innovation/afi…  Contact us -  veracyte.com/company/contac… #ThyroidResearch #ThyroidCancer #Endocrinology #GenomicResearch

We're looking forward to attending #ASCO Annual Meeting in Chicago. The first results from the Phase III #OPTIMA trial evaluating test-directed chemotherapy in breast cancer patients have been selected for oral presentation at #ASCO2026. OPTIMA is a randomized non-inferiority trial assessing #Prosigna test-directed chemotherapy in patients with high clinical risk, ER-positive early breast cancer. The results will be presented by OPTIMA Chief Investigator Prof. Rob Stein of University College London during the Breast Cancer Oral Abstract Session on Saturday, May 30. If you're attending ASCO, stop by our booth #13069. Event info: veracyte.com/company/events… #BreastCancer #PrecisionMedicine #CancerCare #Oncology #ClinicalResearch

Excited to join #AACE in Las Vegas this week! Visit Booth #106 to learn how #Veracyte is using whole-transcriptome-derived analysis on every sample to provide an actionable #AfirmaGSC report and create the potential for novel research. Explore poster presentations highlighting how #Afirma can help guide confident treatment decisions for #thyroidnodules. View Poster and Event Info: veracyte.com/company/event/… Download 2025 Afirma Research Collection: veracyte.com/afirma-2025-re… #AACE2026 #Endocrinology #ThyroidHealth

Join us at #AAES2026 for our Product Theatre presentation demonstrating how #AfirmaGSC is leveraging whole-transcriptome-derived analysis to create the potential for novel thyroid nodule research opportunities. 📅 Date: Saturday, April 18 ⏰ Time: 3:00PM EDT 📍 Location: Ballroom 1, Central Bank Center Visit Booth #15: Stop by to learn how Veracyte is using whole-transcriptome-derived analysis on every sample to provide an actionable Afirma GSC report and to discuss UGFNA tips and techniques with a Clinical Ultrasound Specialists. Event information: veracyte.com/company/event/… #AAES2026 #Endocrinology #ThyroidSurgery #ThyroidNodules

Join us at #AACR for our Spotlight Theater session showcasing how whole-genome sequencing is redefining cancer state and improving patient outcomes in clinical trials. @PhilFebboMD_CMO will introduce our #TrueMRD platform and its utility in tumor-informed ctDNA analysis for monitoring minimal residual disease (MRD). 📅 April 21 | 12:30 PM PST 📍 Theater B, Sails Pavilion, San Diego Convention Center Details: veracyte.com/event/aacr-ann… #AACR2026 #ctDNA #PrecisionMedicine #ClinicalTrials

This week: @PhilFebboMD_CMO, Chief Scientific and Medical Officer at Veracyte, will be speaking at #PMWC26 on the future of whole-genome MRD and precision diagnostics. 📅 March 5, 2:30 PM PST Talk: "Improving Care with Every Test: Powering a Continuous Learning Cycle in Molecular Diagnostics" 💬 March 6, 1:30 PM PST Panel: "Diagnostics, Prognostics, and Patient Stratification" Learn more - pmwcintl.com/speaker/phil-f… #TrueMRD #ctDNA #PrecisionMedicine #OncologyResearch #GenomicTesting #CancerDiagnostics #WholeGenomeSequencing

We are excited to announce that more than 15 abstracts featuring our urology portfolio will be presented this week at the 2026 ASCO Genitourinary Cancers Symposium (#ASCOGU). The abstracts span studies across prostate and bladder cancers, featuring: 🔹 Real-world data for Decipher Prostate 🔹 New insights from phase II clinical trials, including one utilizing our upcoming TrueMRD Muscle-Invasive Bladder Cancer (MIBC) test “The breadth of data at ASCO GU shows how our Veracyte Diagnostics Platform is driving meaningful insight across multiple urologic cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. Read press release - investor.veracyte.com/news-releases/… #Decipher #TrueMRD #MRD #ASCOGU2026 #CancerDiagnostics #UrologicCancer #PrecisionMedicine

Veracyte will report financial results for Q4 and full year 2025 on Wednesday, Feb. 25, at 4:30 PM ET. Join our conference call and webcast for a full financial update and general business overview. 🔗 Access the webcast here: lnkd.in/gTMvRAap #Veracyte #Q4Earnings #FinancialResults #InvestorRelations #Biotech #Diagnostics $VCYT

On Thursday at PM ET, join our live webcast from the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. 🔗 The live audio webcast will be accessible here: investor.veracyte.com/events-present… 📄 Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results: investor.veracyte.com/news-releases/… #FinancialResults $VCYT #CancerDiagnostics #PrecisionMedicine #JPM2026 Disclaimer: veracyte.com/cautionary-not…

Today, we announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter of 2025, compared to the same period in 2024, we expect to report: 🔹Total revenue of between $138 million and $140 million, an increase of between 16% and 18% 🔹Testing revenue of between $134 million and $136 million, an increase of between 19% and 21% 🔹Testing volume of approximately 45,500, an increase of 16% Press Release: investor.veracyte.com/news-releases/… Disclaimer: veracyte.com/cautionary-not… #Veracyte #FinancialResults #Biotech $VCYT #CancerDiagnostics #PrecisionMedicine #JPM2026

#TeamVeracyte is excited to be at #SABCS25 and connect with oncologists, researchers, and colleagues advancing breast cancer care. 🤝 Stop by Booth #1432 to meet our team and discover how the #Prosigna Breast Cancer Assay is helping guide treatment decisions for women with early-stage HR+ breast cancer. We look forward to great conversations and exploring new research. When we get together, breast cancer diagnostics get ahead! #Veracyte #BreastCancer #ProsignaBreastCancerAssay #PrecisionMedicine #MedicalOncology #WomensHealth #BreastCancerResearch #GenomicTesting #PersonalizedMedicine #Oncology #Biotech #CancerCare

As we gather in San Antonio this week for #SABCS25, we're reminded of the importance of precision medicine in breast cancer care. We look forward to connecting with oncologists, researchers, and colleagues, because when we get together, breast cancer diagnostics get ahead. | The Challenge | Globally, breast cancer remains the most common cancer among women, with over 2.3 million new cases reported in 2022. In the US alone, an estimated 319,750 people will be diagnosed with invasive breast cancer in 2025, with about 70% - more than 225,000 - expected to have hormone receptor-positive breast cancer. | Our Approach | At Veracyte, we're committed to providing clinicians with comprehensive genomic insights to confidently guide treatment decisions for patients. Our #Prosigna Breast Cancer Assay helps inform personalized treatment planning for patients with early-stage breast cancer. 🔗 Read our latest article to learn how genomic testing is unlocking the power of truly personalized breast cancer care: linkedin.com/pulse/breast-c… | Connect with us at SABCS 2025 | 🤝 Visit Booth #1432 to connect with #TeamVeracyte and discuss how intrinsic molecular subtyping is transforming treatment decisions for women with HR+ breast cancer. #Veracyte #BreastCancer #ProsignaBreastCancerAssay #PrecisionMedicine #GenomicTesting #PersonalizedMedicine #MedicalOncology #WomensHealth #BreastCancerResearch #ClinicalResearch #Oncology #Biotech #CancerCare

LIVE WEBINAR - Dec 5: Phillip G. Febbo, MD, as he introduces our Veracyte #TrueMRD platform and its utility in tumor-informed circulating tumor DNA (ctDNA) analysis for monitoring minimal residual disease (#MRD), treatment response, and clonal evolution. Gain insights into how WGS-based ctDNA profiling enables: 🔹 Earlier detection of disease recurrence 🔹 Sensitive MRD monitoring 🔹 Deeper whole-genome insights 🔹 More personalized drug development and patient management 📅 Dec 5 | 10am PT / 1pm ET 🔗 Register now: event.on24.com/wcc/r/5116356/… #ctDNA #LiquidBiopsy #PrecisionMedicine #ClinicalTrials

A new UK trial called #INTENSIFY is using the Veracyte #DecipherProstate test to help personalize treatment for advanced prostate cancer patients. The trial will look at whether selecting patients who may require more intensive treatment can improve outcomes for advanced prostate cancer. The aim is to improve survival by delaying the progression of metastatic cancer. 🔹 Read article: southampton.ac.uk/ctu/news/2025/… 🔹 Explore Decipher Prostate: decipherbio.com/decipher-prost… #DecipherUrologicCancers #ProstateCancer #MetastaticProstateCancer #PrecisionMedicine #UrologicOncology #ClinicalTrial #UKResearch #GenomicTesting #PersonalizedMedicine #CancerResearch #Biotech #Urology #AdvancedProstateCancer